50 results on '"Girschikofsky, Michael"'
Search Results
2. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults
3. Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network
4. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
5. Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options—A Single-Center Experience.
6. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine—A prospective cohort study by the AGMT
7. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
8. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial
9. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial
10. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria
11. Successful SARS-CoV-2 mRNA Vaccination Program in Allogeneic Hematopoietic Stem Cell Transplant Recipients—A Retrospective Single-Center Analysis.
12. Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival
13. Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network
14. Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT
15. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)
16. Intensive consolidation with G‐CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years
17. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
18. Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
19. Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia.
20. Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group.
21. Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry
22. PB2134: BCMA‐TARGETED THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION – A SINGLE CENTER EXPERIENCE.
23. Acute myeloid leukemia with TP53 germ line mutations
24. Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group
25. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial.
26. PB2186: MOLECULAR RESPONSE TO INTERFERON IN PREFIBROTIC PRIMARY MYELOFIBROSIS- RETROSPECTIVE SINGLE CENTER STUDY.
27. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
28. Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years
29. A single nucleotide polymorphism at chromosome 2q21.3 (LCT −13910C>T) associates with clinical outcome after allogeneic hematopoietic stem cell transplantation
30. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French- American-British and World Health Organization classifications.
31. Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?
32. Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and
33. Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry
34. Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome
35. Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry
36. Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas.
37. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net.
38. Azacitidine in patients with WHO-defined AML - Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.
39. Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322)
40. Defective DNA-mismatch repair: a potential mediator of leukemogenic susceptibility in therapy-related myelodysplasia and leukemia.
41. Report on Response and Overall Survival of 128 Unselected, Consecutive AML Patients From the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group
42. Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group
43. Response: Significant influence of LCT-13910C>T on transplantation outcomes in acute myeloid leukemia patients receiving transplantations from HLA-identical sibling donors
44. Diagnostic and Prognostic Significance of Tryptase in Clinical Hematology: A Single Center Experience from 1070 Patients.
45. Factors influencing the timing of peripheral blood stem cell collection (PBSC)
46. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.
47. Gemtuzumab Ozogamicin in NPM1 -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.
48. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.
49. Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies.
50. Utility of PCR in diagnosis of invasive fungal infections: real-life data from a multicenter study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.